Checking blood vessel function in pregnant women to predict preeclampsia
Tests vessel and blood tests in pregnant women to see who develops preeclampsia.
Plain-language title generated from the registry record
Registry title: Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
Key facts
- Where
- Bologna, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05999851, who can take part
Where in Italy
- Cardiovascular Internal Medicine Unit, IRCCS University Hospital of Bologna, Bologna, ItalyBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT05999851
- Record updated
- 22 January 2026
- Original description
The present study is a single-centre prospective study that will enrol pregnant women during their first trimester of pregnancy (11+0 - 13+6 weeks of gestation).Read full original descriptionShow less
Multiparametric Assessment of Maternal Vascular Function as a New Diagnostic and Prognostic Tool for Hypertensive Disorders of Pregnancy and Preeclampsia - EDIPE Study
The present study is a single-centre prospective study that will enrol pregnant women during their first trimester of pregnancy (11+0 - 13+6 weeks of gestation).
During pregnancy, women will undergo standard clinical evaluation and management. During the two study visits (enrollment and 24+0 - 27+6 weeks of gestation) the investigators will perform arterial tonometry (Pulsepen) and in vivo darkfield microscopy (Glycocheck) to evaluate endothelial and vascular function. A urine sample and a blood sample for specific study analyses on metabolic profile, endothelial and angiogenic markers will be collected. Pregnancy outcomes will be collected at delivery and five years after delivery all the participants will be interview to collect long-term cardiovascular outcomes. Serum endothelial and angiogenic markers will be evaluated only in participants who will develop hypertensive disorders of pregnancy and in an equal number of controls matched for age and body mass index at the time of conception.
Inclusion: Age greater than or equal to 18 years; Single pregnancy; No previous pregnancies lasting more than 12 weeks; Participant willing and able to give informed consent for participation in the study.
Exclusion: Chronic treatment with antihypertensive drugs and/or xanthine oxidase (XO) inhibitors; History of solid organ or hematopoietic stem cell transplantation; Chronic renal failure (eGFR≤45ml/min/1.73m2); Intermediate-high risk of genetic abnormalities and/or need to perform invasive tests (amniocentesis, villocentesis).